Skip to content
DataLookout
Menu

NCT06415344

Long-term Extension of GTX-102 in Angelman Syndrome

StatusTerminated
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 14 versions: 9 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: Lack of efficacy Show 4 more changesShow less
    • Final enrollment: 66 participants (planned 255)
    • Primary completion date changed from estimate of Feb 2029 to Oct 30, 2026
    • Eligibility criteria expanded, about 7 words
    • Site details revised at 5 of 23 sites
  2. Minor Trial status changed: Enrolling by Invitation → Active, Not Recruitingv13
  3. Notable Primary endpoint(s) modified
    • Eligibility criteria shortened, about 21 words
    • Secondary endpoints: 1 to 2
    v12
  4. Notable Enrollment target: 75 to 255
    • Eligibility criteria expanded, about 91 words
    v9
  5. Minor Site details revised at 1 of 23 sitesv7
Show 3 earlier versionsHide 3 earlier versions
  1. Minor Study sites: 24 to 23v6
  2. Minor Study description shortened, about 6 wordsv5
  3. Notable Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Start date changed from estimate of Aug 2024 to Jul 31, 2024
    v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of Treatment Emergent Adverse Events (TEAEs)
Timeframe: Up to 5 Years

Secondary (2)

Change from Baseline in the Bayley-4 Raw Score
Net Response in Multidomain Responder Index (MDRI)

Arms and interventions

GTX-102Experimental

Participants will receive GTX-102 via intrathecal lumbar puncture (IT LP) on a intrapatient flexible dosing schedule.

Drugs: GTX-102

Sites

23 sites in 8 countries

United States 6, Canada 5, United Kingdom 3, Australia 2, France 2, Germany 2, Spain 2, Israel 1